Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00645307 | A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia. | PHASE3 | COMPLETED | 235 | — | — | May 1, 2004 | Aug 1, 2006 | Jun 8, 2011 | - | — |
| NCT00650793 | A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia | PHASE3 | COMPLETED | 473 | — | — | Mar 1, 2004 | Feb 1, 2006 | Jun 8, 2011 | - | — |
| NCT00838669 | A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone | PHASE1 | COMPLETED | 74 | — | — | Aug 1, 2005 | Dec 1, 2005 | May 18, 2011 | - | — |
| NCT00791232 | A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia | PHASE1 | COMPLETED | 113 | — | — | Mar 1, 2003 | Jun 1, 2003 | Jun 8, 2011 | - | — |
| Name | Type | Description |
|---|---|---|
| Extended Release OROS® Paliperidone | DRUG | - |
| Extended release OROS paliperidone | DRUG | - |
| extended-release (ER) OROS paliperidone | DRUG | - |
Inclusion Criteria: * Subjects who had experienced a recurrence event during the double blind phase of Study R076477-SCH-301 * Remained recurrence free until the end of the double-blind phase, or were in the run-in or stabilization phases when the study was terminated * Who signed the informed cons...